1Istituto di Ricovero e Cura a Carattere Scientifico San Martino, Genova, Italy.
Hematology Am Soc Hematol Educ Program. 2012;2012:223-9. doi: 10.1182/asheducation-2012.1.223.
The outcome of allogeneic stem cell transplantation has improved over the past decades due to a significant reduction of nonrelapse mortality, whereas our ability to control underlying malignant diseases has remained unchanged. Reduction of nonrelapse mortality has been achieved in matched sibling donor transplantation, but perhaps more so with unrelated donor transplantation, in part due to the advances in HLA matching between donor and recipient, but also as a result of improved supportive care, better GVHD prophylaxis, and tailored conditioning regimens. Therefore, over the past decade, results of matched sibling donor and unrelated donor grafts have grown more similar, and the difference in 1-year survival for patients with leukemia has gone from 21% in 1988 in favor of MSD to 9% in 2008. However, due to the significant and combined effect of patient, transplantation, and donor variables, comparisons are made here in the context of defined subsets of patients and specific diseases and in some circumstances also looking at separate studies in children and adults.
过去几十年来，由于非复发死亡率的显著降低，异基因干细胞移植的结果得到了改善，而我们控制潜在恶性疾病的能力仍保持不变。在匹配的同胞供体移植中已经实现了非复发死亡率的降低，但在非亲缘供体移植中可能更为显著，部分原因是供体和受体之间 HLA 匹配的进展，但也是由于支持性护理的改善、更好的移植物抗宿主病预防以及定制的预处理方案。因此，在过去十年中，匹配的同胞供体和非亲缘供体移植的结果变得更加相似，白血病患者的 1 年生存率从 1988 年的 21%有利于 MSD 变为 2008 年的 9%。然而，由于患者、移植和供体变量的显著综合影响，在此处进行的比较是在特定患者亚组和特定疾病的背景下进行的，在某些情况下，也分别在儿童和成人中查看单独的研究。
